

## **Product datasheet for TL311463**

## Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com

**OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200

EU: info-de@origene.com CN: techsupport@origene.cn

## MLH3 Human shRNA Plasmid Kit (Locus ID 27030)

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** MLH3 Human shRNA Plasmid Kit (Locus ID 27030)

Locus ID: 27030
Synonyms: HNPCC7

Vector:pGFP-C-shLenti (TR30023)E. coli Selection:Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

Components: MLH3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 27030).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 001040108, NM 005784, NM 014381, NM 014381.1, NM 014381.2, NM 001040108.1,

BC112167, BC012544, BC036866, BC143729, NM 001040108.2, NM 014381.3

UniProt ID: 09UHC1

Summary: This gene is a member of the MutL-homolog (MLH) family of DNA mismatch repair (MMR)

genes. MLH genes are implicated in maintaining genomic integrity during DNA replication and after meiotic recombination. The protein encoded by this gene functions as a heterodimer with other family members. Somatic mutations in this gene frequently occur in tumors exhibiting microsatellite instability, and germline mutations have been linked to hereditary nonpolyposis colorectal cancer type 7 (HNPCC7). Several alternatively spliced transcript variants have been identified, but the full-length nature of only two transcript variants has

been determined. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).